Recent papers on clinical translation patients therapeutic interventions
Sorted by publication year (newest first) via OpenAlex. List regenerates every 24h.
- 2026
2026 · Cytotherapy · Statham, P., Pararasa, C., Filipiak, M. et al.
- 2026
Abstract SY36-02: Human cancer models: From patient-derived systems to clinical translation
2026 · Cancer Research · Habowski, Amber N., Kouassi, Fatim, Patel, Hardik et al.
- 2026
2026 · The Ewha Medical Journal · Kim, Yong Woon, Park, Seon‐Young, Kang, Seung Joo et al.
- 2026
2026 · Tomography · Park, Yong-Jin, Kim, Il-Hyun, An, Young‐Sil et al.
- 2026
Patient-Specific Disease Modeling with hiPSCs: From Mechanisms to Clinical Translation
2026 · Zenodo (CERN European Organization for Nuclear Research) · science, regenerative medicine
- 2026
2026 · Frontiers in Audiology and Otology · Tian, Xiguang, Cui, Jingwe, Zeng, Shunnian et al.
- 2026
2026 · Zenodo (CERN European Organization for Nuclear Research) · Anonymous, Anonymous, Anonymous
- 2026
2026 · European Urology · Shahini, A., Mehrjoo, Z., Kuasne, H. et al.
- 2026
2026 · Open MIND · Santamaria, Francesca, Baraldi, Eugenio, Cavalieri, Luca et al.
- 2026
2026 · The Italian Journal of Pediatrics/Italian journal of pediatrics · Santamaria, Francesca, Baraldi, Eugenio, Cavalieri, Luca et al.
- 2026
2026 · Disability and Rehabilitation · Wampler, Meredith, Campione, Elizabeth, Newell, Alaina et al.
- 2026
2026 · Discover Oncology · Liu, Jing, Zhao, Hongyan, Zhang, X et al.
- 2026
Metastatic castration-resistant prostate cancer (mCRPC) remains lethal as adaptive resistance to standard of care therapy develops, often driven by AR splice variants alongside transcriptional and translational reprogramming. To identify strategies capable of overcoming these mechanisms, we performed an unbiased high-throughput screen of 2,480 mechanistically annotated compounds across advanced prostate cancer models. Exportin-1 (XPO1)-mediated nuclear export emerged as a critical dependency, and matrix-based combination screening uncovered robust synergy between inhibitors of XPO1 and the translation initiation factor EIF4A1. Dual inhibition induced coordinated disruption of oncogenic protein networks, including AR/AR-V7 and MYC, triggering rapid apoptosis and suppressing cell-cycle and metabolic programs. These effects extended to genetically diverse patient-derived organoids and in vivo xenografts at doses well below established tolerability limits. Together, these findings reveal concurrent control of nuclear export and protein translation as a therapeutic vulnerability in mCRPC, providing a strong rationale for clinical evaluation of XPO1-EIF4A1 co-inhibition to overcome AR-driven resistance.
2026 · Open MIND · Figg, William D
- 2025
A patient‐centred approach to translate remote cognitive assessments into clinical practice
2025 · Alzheimer s & Dementia · Blane, Jasmine, Forster, Shona, Lucas, Anna et al.
- 2025
Translating FRESCO clinical trial evidence into practice: fruquintinib as post-standard third-line therapy followed by trifluridine/tipiracil in a patient with mCRC without targetable mutations.
2025 · PubMed · Biachi, Tiago, Shostak, Jessica
- 2025
2025 · Journal of Translational Medicine · Yang, Jianye, Wu, Tian, Xue, Feiyang et al.
- 2025
2025 · Asian Journal of Medicine and Health · Bhaduri, Rupali, Pal, Arindam, Roy, Anjan et al.
- 2025
2025 · SKIN The Journal of Cutaneous Medicine · Kimball, Alexa B., Garg, Amit, Lev‐Tov, Hadar et al.
- 2025
2025 · Blood · Micin, Katarina, Madarang, Ellen, Nong, Tiffany et al.